Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,730.33
(
0.46%
)
US TECH 100
24,202.40
(
0.78%
)
Dow Jones
47,150.59
(
0.43%
)
Brent Oil
99.20
(
0.91%
)
Bitcoin
74,192.71
(
-0.87%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151628

Friday, 11/02/2012 12:37:54 PM

Friday, November 02, 2012 12:37:54 PM

Post# of 257251

Copaxone is still holding more than 40% of MS drugs market share.

What’s impressive is that Copaxone’s US share of patient Rx’s for MS has not changed to a significant degree from the launch of Gilenya or the uptake in Tysabri from JC-testing. Rather, Copaxone’s US share has remained at or near 40% for the past few years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now